Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | OPRK1 | P41145 | 1/20 | 0.48 |
| ▸ | CHEK2 | O96017 | 3/20 | 0.47 |
| ▸ | ROCK1 | Q13464 | 7/20 | 0.44 |
| ▸ | ROCK2 | O75116 | 4/20 | 0.44 |
| ▸ | KCNH2 | Q12809 | 4/20 | 0.44 |
| ▸ | CCR2 | P41597 | 2/20 | 0.42 |
| ▸ | MCHR1 | Q99705 | 5/20 | 0.41 |
| ▸ | CHRM2 | P08172 | 1/20 | 0.39 |
| ▸ | CHRM3 | P20309 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4991838 | 1.00 | OPRK1 (0.48) | OPRK1CHEK2ROCK1ROCK2KCNH2 | |
| SCHEMBL5253318 | 0.94 | OPRK1 (0.54) | OPRK1CHEK2ROCK1ROCK2KCNH2 | |
| SCHEMBL27598152 | 0.93 | CHEK2 (0.45) | OPRK1CHEK2ROCK1ROCK2KCNH2 | |
| SCHEMBL27598151 | 0.93 | CHEK2 (0.45) | OPRK1CHEK2ROCK1ROCK2KCNH2 | |
| SCHEMBL4995093 | 0.88 | CHEK2 (0.41) | OPRK1CHEK2ROCK1ROCK2KCNH2 | |
| SCHEMBL4995086 | 0.88 | CHEK2 (0.41) | OPRK1CHEK2ROCK1ROCK2KCNH2 | |
| SCHEMBL5252268 | 0.77 | HRH3 (0.53) | OPRK1ROCK1ROCK2KCNH2CCR2 | |
| SCHEMBL10608943 | 0.72 | ROCK1 (0.66) | OPRK1CHEK2ROCK1ROCK2KCNH2 | |
| SCHEMBL10609088 | 0.71 | HRH3 (0.53) | OPRK1CHEK2ROCK1ROCK2KCNH2 | |
| SCHEMBL10607825 | 0.71 | HRH3 (0.62) | OPRK1CHEK2ROCK1ROCK2CCR2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7405305-B2 | Pyrrole-2, 5dione derivatives and their used as GSK-3 inhibitors | ELI LILLY AND COMPANY (US) | 2008-07-29 | — | — | US | disclosed |
| EP-1487822-B1 | PYRROLE-2,5-DIONE DERIVATIVES AND THEIR USE AS GSK-3 INHIBITORS | LILLY CO ELI (US) | 2007-08-01 | — | — | EP | disclosed |
| US-20050288321-A1 | Kinase inhibitors | ELI LILLY AND COMPANY | 2005-12-29 | — | — | US | disclosed |
| CN-1639152-A | Pyrrole-2, 5-dione derivatives and their use as GSK-3 inhibitors | LILLY CO ELI (US) | 2005-07-13 | — | — | CN | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050288321-A1 | Kinase inhibitors | ABL1, MAP3K20, MAP3K19 | OPRK1 1815/4885CHEK2 51/4885ROCK1 383/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.